HOME >> BIOLOGY >> NEWS
Understanding the life of C. elegans

HOUSTON (April 4, 2006) When the nematode Caenorhabditis elegans has enough to eat, enjoys the right temperatures and is not crowded out by its fellows, it produces a hormone, which binds to a receptor called DAF12 that allows it to reach reproductive maturity and live a natural lifespan.

When conditions are harsher, however, the worm a classic model organism frequently studied in the laboratory does not produce the hormone and enters a special stage called the dauer diapause in which it remains an immature larva until the situation improves. In a paper that appears in the journal Developmental Cell, Baylor College of Medicine researchers led by Dr. Adam Antebi, assistant professor in the BCM Huffington Center on Aging and the department of molecular and cellular biology, identify a new gene called DAF-36 involved in making this hormone.

"Our evidence suggests that DAF-36 works early in a pathway that converts cholesterol through a series of enzymatic steps into the dafachronic acids, the active ligands for DAF-12 nuclear receptor," said Antebi. In this instance, a ligand is a molecule that binds to a specific site on a protein.

These particular ligands promote the maturation of the C. elegans reproductive capacity and prevent the organism from going into the immature long-lived larval phase called dauer diapause. Antebi and collaborators identified these ligands in a report that appeared March 24, 2006 in the journal Cell.

In addition, said Antebi, DAF-36 is required for the long life seen in forms of C. elegans that lack germline cells those cells like sperm and egg in animals are necessary for reproduction.

In a related work published in Cell (Motola et al. 2006), the chemical identification of the DAF-12 ligands as steroid-like hormones is reported, providing the first evidence for steroid control of maturation in worms. Antebi speculates that this may resemble how estrogen and androgen hormones similarly gover
'"/>

Contact: Kimberlee Barbour
kbarbour@bcm.edu
713-798-4712
Baylor College of Medicine
4-Apr-2006


Page: 1 2

Related biology news :

1. Understanding why C. difficile causes disease -- its hungry
2. Understanding the global carbon budget -- Woods Hole Research Center expert provides insights
3. Understanding occupational safety and health issues of nanotechnology
4. Understanding the Arctic -- NSF-funded expeditions cover new ground in climate science
5. Understanding climate change: Public forum in Philadelphia next week
6. Understanding food nutrition labels challenging for many people
7. Understanding of cell protection mechanism points to therapies to prevent heart attacks and strokes
8. Drawing a crowd: Understanding the signals that bring inflammatory cells into the lung
9. Jane Lubchenco receives the 2005 AAAS Public Understanding of Science and Technology Award
10. Understanding the oceans microbes is key to the Earths future
11. Understanding IGF-1: Jefferson researcher sees drug potential in targeting enzyme

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Understanding the life elegans

(Date:5/10/2015)... , May 11, 2015 Fingerprint ... sensors FPC1025 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... will be used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK for ...
(Date:5/7/2015)... May 7, 2015 Fingerprint ... FPC1022 and FPC1035, FPC,s smallest touch fingerprint sensors ... mainly considered for integration on the backside of ... OEMs increased possibilities to integrate touch fingerprint sensors ... also improves possibilities for module manufacturers to customize ...
(Date:5/5/2015)... 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, reminds investors and media that  Mr. ... presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of ... themed Global Fraud: Where is the Trust in Cyberspace? ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) ... focused on the development of autologous cell therapies, ... International Society for Cellular Therapy (ISCT) on RepliCel,s ... in a Phase 1/2 clinical trial.  The presentation, ... 5:30 PM to 7:00 PM local time, will ...
(Date:5/20/2015)... 20, 2015 Veracyte, Inc . ... demonstrating the ability of the company,s molecular classifier ... other interstitial lung diseases (ILDs) using samples obtained ... to help thousands of patients avoid invasive, risky ... diagnosis – a frequent challenge for physicians and ...
(Date:5/20/2015)... and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ) has announced ... Outlook 2020 " report to their offering. ... medicine is expected to have huge marketing potential. Presently, ... the growth of deregulated organs. Several therapeutic molecules are ... form new tissue or sometimes organ transplant is required. ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
Cached News: